IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders
IL-5 CAR-T cell therapy represents a promising targeted therapeutic approach for IL-5Rα<sup>+</sup> hypereosinophilic disorders. Its ability to target eosinophils and their precursors across all developmental stages in BM and PB addresses a critical unmet medical need in refractory HES and CEL.
Authors
- Youqian Wu
- Zhehua Shao (ORCID: https://orcid.org/0000-0003-2719-950X)
- Sheng Pan (ORCID: https://orcid.org/0000-0002-3085-6825)
- Haoyu Tang (ORCID: https://orcid.org/0000-0002-0083-4115)
- Gaoying Chen
- Dan Shen (ORCID: https://orcid.org/0000-0002-2231-0224)
- Songmin Ying (ORCID: https://orcid.org/0000-0001-7053-0793)
- Beibei Sun
- Yongxian Hu
- Jiayuan Zeng
- Jiawei Shao
- Ruiqi Zhang
- Bingpeng Yao
- Qian Wu
- Chao Zhang
- Fan Shi
- Xinyi Chen
- Fang Xu
- Dongrui Wang
Institutions
- Zhejiang International Studies University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1186/s13045-026-01782-x
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00